You are here:

Forthcoming Submission: selexipag (Uptravi)

Indication: For the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.

Drug Details

Drug Name: selexipag (Uptravi)
Drug Manufacturer: Actelion Pharmaceuticals UK Ltd
BNF Category:
Submission type: Resubmission
Patient Interest Group
Submission Deadline:
SMC Meeting Date: 3/04/2018
Advice Due: 7/05/2018